Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Biol Psychol ; 138: 172-178, 2018 10.
Article in English | MEDLINE | ID: mdl-30253231

ABSTRACT

Interpersonal violence (IPV) is one of the most frequent causes for the development of posttraumatic stress disorder (PTSD) in women. One key component in PTSD is altered processing of trauma-related cues, leading to emotional symptoms. In the everyday environment, words with trauma-associated semantic content represent typical, albeit abstract, trauma-related stimuli for patients suffering from PTSD. However, the functional neuroanatomy associated with processing single trauma-related words in IPV-PTSD is not understood. The present event-related functional magnetic resonance imaging study investigated the neural basis of trauma-related word processing in women with IPV-PTSD relative to healthy controls (HC) during a non-emotional vigilance task in which the emotional content of the words was task-irrelevant. On the behavioral level, trauma-related relative to neutral word stimuli evoked more unpleasant feelings, higher arousal as well as anxiety in IPV-PTSD patients as compared to HC. Functional imaging data showed hyperactivation to trauma-related versus neutral words in the basolateral amygdala (BLA) and cortical language-processing regions (inferior frontal gyrus, posterior cingulate cortex, angular/supramarginal gyrus) in IPV-PTSD compared to HC. These results propose a role of the BLA in hypervigilant responding to verbal trauma associated cues in IPV-PTSD. Furthermore, the particular involvement of cortical language-processing regions indicates enhanced processing of trauma-related words in brain regions associated with analysis and memory of verbal material. Taken together, our findings suggest that both subcortical and cortical mechanisms contribute to automatic responsivity to verbal trauma cues in PTSD.


Subject(s)
Basolateral Nuclear Complex/physiopathology , Cerebral Cortex/physiopathology , Functional Neuroimaging/methods , Intimate Partner Violence , Language , Stress Disorders, Post-Traumatic/physiopathology , Adult , Female , Humans , Magnetic Resonance Imaging
2.
Psychol Med ; 48(7): 1209-1217, 2018 05.
Article in English | MEDLINE | ID: mdl-28950918

ABSTRACT

BACKGROUND: Altered amygdala activation to fear-related stimuli has been proposed to be a potential neural correlate of heightened threat sensitivity in anxiety- and stress-related disorders. However, the role of stimulus awareness and disorder specificity remains widely unclear. Here we investigated amygdala responses to conscious and unconscious fearful faces in patients suffering from panic disorder (PD), generalized anxiety disorder (GAD), or post-traumatic stress disorder (PTSD) and in a large sample of healthy controls (HC). METHODS: During event-related functional magnetic resonance imaging participants (n = 120; 20 PD, 20 GAD, 20 PTSD, 60 HC) were confronted with briefly presented fearful faces, neutral faces, and non-faces in a backward masking paradigm. The design allowed for the analysis of trial-by-trial face detection performance and amygdala responses to fearful v. neutral faces. RESULTS: All participants exhibited increased amygdala activation to fearful v. neutral faces during conscious trials. Specifically during unconscious face processing, the PTSD, compared with all other groups, showed higher right basolateral (BLA) amygdala activity to fearful v. neutral faces. CONCLUSIONS: The present study shows that BLA amygdala hyperactivity during unconscious, but not conscious, processing of fearful faces differentiates PTSD from the investigated disorders. This finding suggests an automatic and specific neural hyper-responsivity to general fear cues in PTSD and supports the idea of categorical differences between PTSD and other anxiety-related disorders.


Subject(s)
Amygdala/physiopathology , Anxiety Disorders/physiopathology , Fear/physiology , Stress Disorders, Post-Traumatic/physiopathology , Adolescent , Adult , Case-Control Studies , Cues , Facial Expression , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Panic Disorder/physiopathology , Reaction Time , Regression Analysis , Young Adult
3.
Psychol Med ; 47(4): 730-743, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27869064

ABSTRACT

BACKGROUND: There is an ongoing debate whether transdiagnostic neural mechanisms are shared by different anxiety-related disorders or whether different disorders show distinct neural correlates. To investigate this issue, studies controlling for design and stimuli across multiple anxiety-related disorders are needed. METHOD: The present functional magnetic resonance imaging study investigated neural correlates of visual disorder-related threat processing across unmedicated patients suffering from panic disorder (n = 20), social anxiety disorder (n = 20), dental phobia (n = 16) and post-traumatic stress disorder (n = 11) relative to healthy controls (HC; n = 67). Each patient group and the corresponding HC group saw a tailor-made picture set with 50 disorder-related and 50 neutral scenes. RESULTS: Across all patients, increased activation to disorder-related v. neutral scenes was found in subregions of the bilateral amygdala. In addition, activation of the lateral amygdala to disorder-related v. neutral scenes correlated positively with subjective anxiety ratings of scenes across patients. Furthermore, whole-brain analysis revealed increased responses to disorder-related threat across the four disorders in middle, medial and superior frontal regions, (para-)limbic regions, such as the insula and thalamus, as well as in the brainstem and occipital lobe. We found no disorder-specific brain responses. CONCLUSIONS: The results suggest that pathologically heightened lateral amygdala activation is linked to experienced anxiety across anxiety disorders and trauma- and stressor-related disorders. Furthermore, the transdiagnostically shared activation network points to a common neural basis of abnormal responses to disorder-related threat stimuli across the four investigated disorders.


Subject(s)
Amygdala/physiopathology , Brain/physiopathology , Dental Anxiety/physiopathology , Fear/physiology , Panic Disorder/physiopathology , Phobia, Social/physiopathology , Stress Disorders, Post-Traumatic/physiopathology , Adult , Amygdala/diagnostic imaging , Brain/diagnostic imaging , Dental Anxiety/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Male , Panic Disorder/diagnostic imaging , Phobia, Social/diagnostic imaging , Stress Disorders, Post-Traumatic/diagnostic imaging , Visual Perception/physiology , Young Adult
4.
Haemophilia ; 22(5): 730-8, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27434619

ABSTRACT

BACKGROUND: rVIII-SingleChain, a novel recombinant factor VIII (rFVIII), has been designed as a B-domain truncated construct with covalently bonded heavy and light chains, aiming to increase binding affinity to von Willebrand factor (VWF). Preclinical studies confirmed greater affinity for VWF, giving improved pharmacokinetic and pharmacodynamic properties compared with full-length rFVIII. AIM: To investigate the pharmacokinetics of rVIII-SingleChain and compare them against those of full-length rFVIII. METHODS: This study enrolled 27 patients with severe haemophilia A in the AFFINITY clinical trial programme. After a 4-day washout period, all patients received a single infusion of 50 IU kg(-1) octocog alfa (Advate(®) ); after a ≥4-day postinfusion washout period, they received a single infusion of 50 IU kg(-1) rVIII-SingleChain. Blood samples for pharmacokinetic assessments of each product were collected before infusion (predose) and at 0.5, 1, 4, 8, 10, 24, 32, 48 and 72 h postinfusion for both products. RESULTS: rVIII-SingleChain had a longer mean half-life (t1/2 ) (14.5 vs. 13.3 h), lower mean clearance (CL) (2.64 vs. 3.68 mL h(-1) kg(-1) ), higher mean residence time (20.4 vs. 17.1 h) and larger mean AUCinf (2090 vs. 1550 IU?h dL(-1) ) than octocog alfa, respectively. The mean AUCinf after rVIII-SingleChain infusion was ~35% larger than after octocog alfa. A similar pattern was observed for AUC0-last . No serious adverse events or inhibitors were reported. CONCLUSIONS: rVIII-SingleChain has a favourable pharmacokinetic profile compared with octocog alfa and was well tolerated. The prolonged t1/2 , larger AUC and reduced CL of rVIII-SingleChain may permit longer dosing intervals, thereby improving patient adherence to prophylactic treatment.


Subject(s)
Coagulants/therapeutic use , Factor VIII/therapeutic use , Hemophilia A/drug therapy , Adolescent , Adult , Aged , Antibodies, Neutralizing/blood , Area Under Curve , Blood Coagulation Tests , Coagulants/pharmacokinetics , Drug Administration Schedule , Factor VIII/analysis , Factor VIII/pharmacokinetics , Half-Life , Humans , Male , Middle Aged , ROC Curve , Severity of Illness Index , Treatment Outcome , Young Adult
5.
Haemophilia ; 21(3): 343-350, 2015 May.
Article in English | MEDLINE | ID: mdl-25582282

ABSTRACT

In haemophilia A patients factor VIII (FVIII) recovery and half-life can vary substantially. There are parameters known to modulate FVIII pharmacokinetics (PK), but they explain only about 34% of the variability. The aim of this study was to identify new parameters that influence FVIII PK and thus to expand the current knowledge. FVIII PK were determined in 42 haemophilia A patients (37 severe, 5 moderate) without inhibitor. Patients' characteristics and laboratory parameters were evaluated for an association with FVIII PK. We analysed plasma levels of low-density lipoprotein receptor-related protein 1 (LRP1) and protein C (PC) activity, which had been hypothesized to influence FVIII activity. Furthermore, four variations in intron 6 of the LRP1 gene, which had been shown to influence LRP1, were investigated. FVIII half-life differed widely from 6.2 to 20.7 h, with a median of 10.0 h. Patients with blood group O had shorter FVIII half-life compared to patients with non-O blood group (median FVIII half-life 9.0 h vs. 10.4 h, P = 0.018). Age was significantly associated with FVIII half-life (r = 0.32, P = 0.035). Besides age, also VWF antigen (r = 0.52, P < 0.001) and blood group (r = -0.37, P = 0.015) was associated with FVIII half-life. No correlation was found with FVIII- or LRP1-genotype, LRP1 or PC concentrations. Our data showed large differences in FVIII PK between individual patients and revealed age, blood group and VWF levels as important determining factors for FVIII half-life. FVIII genotype or levels of LRP1 or PC had no influence on FVIII PK.


Subject(s)
Factor VIII/pharmacokinetics , Factor VIII/therapeutic use , Hemophilia A/drug therapy , Recombinant Proteins , ABO Blood-Group System , Adult , Age Factors , Blood Coagulation , Body Mass Index , Factor VIII/administration & dosage , Half-Life , Hemophilia A/blood , Hemophilia A/diagnosis , Humans , Low Density Lipoprotein Receptor-Related Protein-1/genetics , Male , Mutation , Polymorphism, Single Nucleotide , Severity of Illness Index , Treatment Outcome , Young Adult , von Willebrand Factor
6.
Br J Cancer ; 111(1): 55-60, 2014 Jul 08.
Article in English | MEDLINE | ID: mdl-24874478

ABSTRACT

BACKGROUND: High levels of C-reactive protein (CRP), an acute phase protein, proofed being associated with decreased clinical outcome in small-scale studies in diffuse large B-cell lymphoma (DLBCL). The aim of this study was to evaluate the prognostic impact of pretreatment CRP levels on overall survival (OS) and disease-free survival (DFS) in a large bicentre study of DLBCL patients. METHODS: Data from 477 DLBCL patients, diagnosed and treated between 2004 and 2013 at two Austrian centres, were evaluated retrospectively. The prognostic influence of CRP and other factors, including age, tumour stage, and revised International Prognostic Index (R-IPI) on 5-year OS and 5-year DFS, were studied by Kaplan-Meier curves as well as univariate and multivariate Cox regression models. Influence of CRP on the predictive accuracy of the R-IPI score was determined by the Harrell concordance index. RESULTS: Kaplan-Meier curves revealed elevated CRP as a factor for decreased 5-year OS and DFS in DLBCL patients (P<0.001, log-rank test). An independent significant association between high CRP levels and poor clinical outcome in multivariate analysis for 5-year OS (HR=1.51, CI 95%=1.04-2.20, P=0.031) and for DFS (HR=1.91, CI 95%=1.28-2.85, P=0.002) was found. The estimated concordance index was 0.75 using the original R-IPI score and 0.79 when CRP was added. CONCLUSIONS: In the present study, we demonstrated high CRP levels at diagnosis of DLBCL as an independent poor prognostic factor for clinical outcome. Adding CRP to the well-established prognostic models such as the R-IPI score might improve their predictive ability.


Subject(s)
C-Reactive Protein/metabolism , Lymphoma, Large B-Cell, Diffuse/blood , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies
7.
Br J Cancer ; 110(2): 369-74, 2014 Jan 21.
Article in English | MEDLINE | ID: mdl-24357794

ABSTRACT

BACKGROUND: With growing evidence on the role of inflammation in cancer biology, the systemic inflammatory response has been postulated as having prognostic significance in a wide range of different cancer types. Recently, the derived neutrophil to lymphocyte ratio (dNLR) has been proposed as an easily determinable prognostic factor in cancer patients. Nevertheless, its prognostic significance in diffuse large B-cell lymphoma (DLBCL) patients has never been explored. METHODS: Data from 290 consecutive DLBCL patients, diagnosed between 2004 and 2013 at a single Austrian centre, were evaluated retrospectively. The prognostic influence of the dNLR and other clinico-pathological factors including age, lactate dehydrogenase, cell of origin category and Ann Arbor stage on 5-year overall- (OS) and disease-free (DFS) survival was studied by Kaplan-Meier curves. To evaluate the independent prognostic relevance of dNLR, univariate and multivariate Cox regression models were applied. RESULTS: An independent significant association between high dNLR and poor clinical outcome in multivariate analysis for OS (HR=2.02, confidence interval (CI) 95%=1.17-3.50, P=0.011), as well as DFS (HR=2.15, CI 95%=1.04-4.47, P=0.038), was identified. CONCLUSION: In the present study, we showed that a high dNLR at diagnosis of DLBCL represents an independent poor prognostic factor for clinical outcome. Our data encourage the further validation of this easily available parameter in prospective studies and as a potential stratification tool in clinical trials.


Subject(s)
Lymphocytes/pathology , Lymphoma, Large B-Cell, Diffuse/blood , Neutrophils/pathology , Aged , Disease-Free Survival , Female , Humans , Inflammation/blood , Inflammation/pathology , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Prognosis , Retrospective Studies
8.
Bone Marrow Transplant ; 48(6): 799-802, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23208316

ABSTRACT

Blastic plasmacytoid DC neoplasm (BPDCN) is a rare haematopoietic malignancy with an aggressive behaviour. We evaluated five patients allografted as consolidative treatment with an unrelated donor in first or subsequent remission. Four patients received a reduced intensity-conditioning regimen because of age or co-morbidities. As the stem cell sources, two umbilical cord blood-(UCB), two PBSC- and one BM graft were used. No GVHD was observed in the patients who received a UCB graft. However, both developed a post-transplant-associated lymphoproliferative disease. So far, only one patient has experienced relapse and was consecutively treated by escalated donor lymphocyte infusions (DLI). A potent graft-versus-leukaemia (GVL) effect was induced leading to a 17-month-long CR. Four patients are still in ongoing CR with median disease-free and overall survivals of 17 and 21 months. Thus, allogeneic SCT in BPDCN offers a potential curative option for patients with a compatible donor. UCB is an attractive alternative as a stem cell source. For relapsing patients, DLI can exert a powerful GVL effect.


Subject(s)
Graft vs Leukemia Effect , Lymphoproliferative Disorders/therapy , Neoplasms, Plasma Cell/therapy , Stem Cell Transplantation , Transplantation Conditioning , Adult , Disease-Free Survival , Female , Follow-Up Studies , Humans , Lymphoproliferative Disorders/etiology , Lymphoproliferative Disorders/mortality , Male , Middle Aged , Neoplasms, Plasma Cell/mortality , Survival Rate , Time Factors , Unrelated Donors
11.
J Pathol ; 215(4): 431-44, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18561120

ABSTRACT

Chemokine receptors mediate migration and activation of lymphocytes through binding of their ligands. Recent studies have revealed important contributions of chemokine receptors to the development, progression, and dissemination of haematopoietic neoplasms. Because the chemokine receptor expression profile in extragastric MALT lymphoma is unknown, we performed a comprehensive study on tissue samples of parotid glands, parotid glands affected by Sjögren syndrome, extragastric MALT lymphoma, and extranodal diffuse large B-cell lymphoma (eDLBCL) originating from MALT lymphoma (transformed MALT lymphoma). By investigating the expression of 19 chemokine receptors by real-time PCR using a semi-quantitative approach and of four chemokine receptors (CCR1, CCR5, CXCR6, and XCR1) by immunohistochemistry, we show that the chemokine receptor expression profiles of extragastric MALT lymphomas differ substantially from those of extranodal DBLCL, with lower expression of CCR1, CCR8, and CXCR3, and the absence of expression of CX3CR1 and XCR1 in eDLBCL. Expression of CCR6, CCR7, CXCR3, CXCR4, and CXCR5, responsible for B-cell homing to secondary lymphoid tissue, was detected in both B-cell malignancies. Expression of CCR4 was just detected in trisomy 3-positive MALT lymphoma cases. Comparing gastric with extragastric MALT lymphomas, up-regulation of CXCR1 and CXCR2 accompanied by down-regulation of CCR8 and CX3CR1 and loss of XCR1 expression in extragastric MALT lymphomas appear to be key determinants for the site of origin of MALT lymphomagenesis. Our results support a model of stepwise progression of extragastric MALT lymphoma from a non-neoplastic event to Sjögren syndrome, to MALT lymphoma, and finally to overt eDLBCL, guided by differentially expressed B-cell homeostatic and activation-dependent chemokine receptors and their ligands.


Subject(s)
B-Lymphocytes/metabolism , Lymphoma, B-Cell, Marginal Zone/metabolism , Receptors, Chemokine/genetics , Disease Progression , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Interphase , Lymphoma, Large B-Cell, Diffuse/metabolism , Parotid Gland/metabolism , Receptors, CCR1/analysis , Receptors, CCR1/genetics , Receptors, CCR5/analysis , Receptors, CCR5/genetics , Receptors, CXCR4/genetics , Receptors, CXCR6 , Receptors, Chemokine/analysis , Receptors, G-Protein-Coupled/analysis , Receptors, G-Protein-Coupled/genetics , Receptors, Virus/analysis , Receptors, Virus/genetics , Reverse Transcriptase Polymerase Chain Reaction , Sjogren's Syndrome/metabolism , Statistics, Nonparametric , Trisomy
12.
Bone Marrow Transplant ; 42(4): 275-9, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18500368

ABSTRACT

In this multicenter study, 30 patients undergoing matched related or unrelated allogeneic stem-cell transplantation for leukemia were treated with palifermin, and retrospectively compared to a matched control group. Palifermin recipients transplanted with an unrelated donor showed a significant reduction of severity, incidence and duration of oral mucositis WHO grades 2-4. In addition, in the palifermin group the use of opioid analgesics and the duration of total parenteral nutrition decreased, whether stem cells were used from matched related or unrelated donors. No beneficial influence of palifermin on the incidence and severity of acute GVHD (aGVHD) was apparent. The incidence and duration of febrile neutropenia, documented infections, hematopoietic recovery or overall survival remained unchanged. The most common adverse effects included rash or erythema, generally mild and transient in appearance. Thus, the administration of palifermin was generally well tolerated and safe, and significantly reduced oral mucositis whereas--regardless of donor status--no effect on the incidence and severity of aGVHD was seen.


Subject(s)
Fibroblast Growth Factor 7/therapeutic use , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation/methods , Leukemia/therapy , Stomatitis/prevention & control , Adolescent , Adult , Female , Fibroblast Growth Factor 7/adverse effects , Humans , Male , Middle Aged , Retrospective Studies , Transplantation Conditioning , Transplantation, Homologous
15.
Vox Sang ; 89(4): 257-60, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16262760

ABSTRACT

BACKGROUND AND OBJECTIVES: Host- or donor-derived alloimmune thrombocytopenia can develop after non-myeloablative allogeneic haematopoietic stem cell transplantation (HSCT). We report the first case of host-derived HPA-1a antibodies. CASE REPORT: A 52-year-old male patient received HSCT from his human leucocyte antigen (HLA)-A, -B, -C, -DR identical brother after reduced intensity conditioning. Bilinear engraftment around day 12 was accompanied by a continuous decrease of platelet counts. We investigated for platelet antibodies because of a progressive decline of platelet counts and refractoriness to platelet transfusions. METHODS: The patient's serum was tested by enzyme-linked immunosorbent assay (ELISA), a solid phase assay and monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay. Recipient's DNA from the time before HSCT and donor's DNA were genotyped for human platelet antigens. RESULTS: Serum obtained on day 15 after HSCT reacted strongly with the donor's platelets due to host-derived anti-HPA-1a- and anti-HLA I antibodies. Serum samples from days 39, 45 and 65 after HSCT contained only anti-HLA I; no antibodies were detectable on day 149. Platelet counts increased on day 20 spontaneously. The decrease of the antibodies accompanied by the increase of the platelet counts suggests progressive elimination of residual host cells. CONCLUSIONS: The HPA-1a antibodies affected thrombopoietic engraftment and the success of platelet transfusions.


Subject(s)
Antigens, Human Platelet , Autoantibodies , Hematopoietic Stem Cell Transplantation , Multiple Myeloma/complications , Platelet Transfusion , Purpura, Thrombocytopenic, Idiopathic/etiology , Antigens, Human Platelet/immunology , Autoantibodies/immunology , Graft Survival/immunology , Humans , Integrin beta3 , Male , Middle Aged , Multiple Myeloma/immunology , Multiple Myeloma/therapy , Purpura, Thrombocytopenic, Idiopathic/immunology , Transplantation, Homologous
16.
Bone Marrow Transplant ; 35(9): 889-93, 2005 May.
Article in English | MEDLINE | ID: mdl-15765110

ABSTRACT

Infectious complications are frequent events in patients undergoing high-dose cytotoxic chemotherapy with subsequent autologous peripheral blood stem cell transplantation (PBSCT). To evaluate whether a single subcutaneous injection of pegfilgrastim (6 mg) is as safe and effective as daily filgrastim (5 mug/kg/day), 60 consecutive autologous stem cell transplantations performed for various haematological malignancies have been analysed. In total, 24 patients undergoing 30 consecutive PBSCT received a single subcutaneous injection of 6 mg pegfilgrastim on day 5 after transplantation and were compared retrospectively with 30 patients receiving 5 mug/kg/day of filgrastim starting from day 7 post transplantation. The mean duration of grade 4 neutropenia in the pegfilgrastim and filgrastim groups was 8.3 and 9.5 days, respectively (P=0.047). The results of the two groups were not significantly different for incidence of febrile neutropenia and toxicity profile. However, duration of febrile neutropenia (1.6 vs 3.0 days) and total days of fever (1.73 vs 4.1) were different (P=0.017 and 0.003, respectively), favouring the pegfilgrastim arm. Consequently, a higher incidence of transplants with documented infectious complications associated with the filgrastim group could be observed (56 vs 26%) (P=0.02). A single injection of pegfilgrastim administered at day 5 post transplant shows comparable safety and efficacy profiles to daily injections of filgrastim.


Subject(s)
Granulocyte Colony-Stimulating Factor/administration & dosage , Hematologic Neoplasms/therapy , Lymphoproliferative Disorders/therapy , Neutropenia/drug therapy , Peripheral Blood Stem Cell Transplantation , Adult , Aged , Female , Filgrastim , Hematologic Neoplasms/complications , Humans , Injections, Subcutaneous , Lymphoproliferative Disorders/complications , Male , Middle Aged , Neutropenia/etiology , Polyethylene Glycols , Recombinant Proteins , Transplantation, Autologous
17.
Nature ; 412(6844): 341-6, 2001 Jul 19.
Article in English | MEDLINE | ID: mdl-11460166

ABSTRACT

Genomic instability promotes tumorigenesis and can occur through various mechanisms, including defective segregation of chromosomes or inactivation of DNA mismatch repair. Although B-cell lymphomas are associated with chromosomal translocations that deregulate oncogene expression, a mechanism for genome-wide instability during lymphomagenesis has not been described. During B-cell development, the immunoglobulin variable (V) region genes are subject to somatic hypermutation in germinal-centre B cells. Here we report that an aberrant hypermutation activity targets multiple loci, including the proto-oncogenes PIM1, MYC, RhoH/TTF (ARHH) and PAX5, in more than 50% of diffuse large-cell lymphomas (DLCLs), which are tumours derived from germinal centres. Mutations are distributed in the 5' untranslated or coding sequences, are independent of chromosomal translocations, and share features typical of V-region-associated somatic hypermutation. In contrast to mutations in V regions, however, these mutations are not detectable in normal germinal-centre B cells or in other germinal-centre-derived lymphomas, suggesting a DLCL-associated malfunction of somatic hypermutation. Intriguingly, the four hypermutable genes are susceptible to chromosomal translocations in the same region, consistent with a role for hypermutation in generating translocations by DNA double-strand breaks. By mutating multiple genes, and possibly by favouring chromosomal translocations, aberrant hypermutation may represent the major contributor to lymphomagenesis.


Subject(s)
B-Lymphocytes , DNA-Binding Proteins , Lymphoma, B-Cell/genetics , Lymphoma, Large B-Cell, Diffuse/genetics , Mutation , Proto-Oncogenes , Transcription Factors , DNA Mutational Analysis , Genes, myc , Germinal Center/cytology , Humans , Lymphoma, B-Cell/immunology , Lymphoma, Large B-Cell, Diffuse/immunology , Molecular Sequence Data , PAX5 Transcription Factor , Proteins/genetics
18.
Leuk Lymphoma ; 40(3-4): 345-9, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11426556

ABSTRACT

Ineffective hematopoiesis leading to profound cytopenias represents a major clinical problem in the management of patients with myelodysplastic syndrome (MDS). The aminothiol amifostine has shown to promote multilineage hematopoiesis both in vivo and in vitro in patients with MDS. We have treated 10 patients with 250 mg/m2 amifostine thrice weekly in combination with erythropoietin for 4 consecutive weeks followed by 2 weeks observation. Responding patients received the same 6 week schedule, while nonresponder received G-CSF in addition to erythropoietin and amifostine during the second treatment course. All patients experienced single or multilineage hematologic improvement, but only 2 reached transfusion independency. Moreover, response was durable only in a minority of patients and thus additional studies are warranted to further define the potential interaction of amifostine and growth factors.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Hematopoiesis/drug effects , Myelodysplastic Syndromes/drug therapy , Aged , Aged, 80 and over , Amifostine/administration & dosage , Amifostine/pharmacology , Amifostine/toxicity , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/toxicity , Blood Cell Count , Cell Lineage , Erythropoietin/administration & dosage , Erythropoietin/pharmacology , Erythropoietin/toxicity , Granulocyte Colony-Stimulating Factor/administration & dosage , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte Colony-Stimulating Factor/toxicity , Humans , Middle Aged , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/complications , Treatment Outcome
19.
Leukemia ; 15(4): 635-41, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11368367

ABSTRACT

From 1987 to 1999 35 patients with poor prognosis non-Hodgkin's lymphoma (NHL) underwent allogeneic stem cell transplantation (SCT) at the University Hospitals of Vienna and Graz. Initial biopsy specimens were reclassified according to the Revised European-American Classification of Lymphoid Neoplasms (REAL). All patients surviving 28 days engrafted. Twenty-eight of them (93%) attained clinical remission. At the last follow-up 14 patients were alive and disease-free at a median of 5.0 (range, 2.3-12.9) years after allogeneic SCT. The actuarial overall survival is 35%. Five patients relapsed 1.8 to 27.6 months after transplant, the probability of relapse is 23%. Of the 21 deaths following SCT, seven were due to relapse/refractory disease and 14 due to transplant-related causes. The probability of treatment-related mortality is 48%. After SCT, minimal residual disease (MRD) was monitored by polymerase chain reaction (PCR) in seven patients with a BCL-2/IgH translocation and in 13 with a clonal immunoglobulin heavy chain (IgH) rearrangement. All 20 patients attained clinical remission rapidly and converted to PCR negativity. In the follow-up nine of these patients are in long-term clinical and molecular remission, six PCR-negative patients died of transplant-related causes and five patients relapsed. In summary, allogeneic stem cell transplantation has a curative potential for patients with refractory and recurrent non-Hodgkin's lymphoma. In our series long-term disease-free survival was associated with molecular disease eradication after SCT. Treatment-related mortality rate was high, thus earlier referral of selected patients to allogeneic SCT should be considered.


Subject(s)
Hematopoietic Stem Cell Transplantation , Lymphoma, Non-Hodgkin/therapy , Adult , Female , Gene Rearrangement , Genes, Immunoglobulin , Genes, bcl-2 , Graft vs Host Disease/etiology , Humans , Immunoglobulin Heavy Chains/genetics , Lymphoma, Non-Hodgkin/genetics , Lymphoma, Non-Hodgkin/mortality , Male , Middle Aged , Polymerase Chain Reaction , Prognosis , Transplantation, Homologous
20.
Ann Hematol ; 80(2): 119-20, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11261323

ABSTRACT

Monoclonal antibodies recognizing hematopoietic antigens are increasingly being used to target therapy directly at leukemic cells, with the aim of achieving sustained remission with little systemic toxicity. Administration of anti-CD33 calicheamicin immunoconjugate is commonly regarded as being safe, with only moderate systemic non-hematological side effects. We report on two cases of hepatic veno-occlusive disease in heavily pretreated patients presenting with relapsed acute myeloid leukemia (AML). Since significant liver toxicity prevented further specific therapy in both patients, we recommend that antibody therapy with anti-CD33 immunoconjugate should be applied with caution in patients presenting with risk factors for the development of hepatic veno-occlusive disease.


Subject(s)
Aminoglycosides , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Hepatic Veno-Occlusive Disease/complications , Immunotoxins/therapeutic use , Leukemia, Myeloid/drug therapy , Acute Disease , Antibodies, Monoclonal, Humanized , Female , Gemtuzumab , Humans , Male , Middle Aged , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...